Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City. The company will engage in a Fireside Chat on Tuesday, May 20 at 10:30 AM EDT at NASDAQ. Additionally, TBPH will conduct in-person meetings with the investment community during the conference.

Investors can access the webcast through Theravance's website under the Investors section, Events and Presentations. The webcast recording will remain available for replay on the company's website for 30 days following the event.

Theravance Biopharma (NASDAQ: TBPH) presented analyses of its Phase 3 program for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the International MSA Congress. The subgroup analysis from the REDWOOD 0170 study showed that Multiple System Atrophy (MSA) patients experienced meaningful improvement in nOH symptoms after 16 weeks of treatment, with symptoms remaining stable in the ampreloxetine group while worsening in the placebo group.

Key findings revealed improved functional activities in treated patients and demonstrated ampreloxetine's sustained effect on standing blood pressure. Additional analysis from Study 0169 highlighted that MSA patients had the highest nOH symptom burden despite existing treatments, emphasizing the need for better therapies. These results support the ongoing CYPRESS registrational study in nOH and MSA patients.

Theravance Biopharma (TBPH) reported its Q1 2025 financial results, highlighting strong performance across key products. YUPELRI achieved US net sales of $58.3 million, up 6% year-over-year, with notable 48% growth in hospital channel doses. TRELEGY posted global net sales of $854 million, representing a 14% increase from Q1 2024.

The company reported total revenue of $15.4 million and a net loss of $13.6 million. Quarter-end cash balance stood at $130.9 million with no debt. R&D expenses were $11.5 million, while SG&A expenses reached $18.4 million.

The CYPRESS study for ampreloxetine, targeting neurogenic orthostatic hypotension in MSA patients, is nearing completion with final patient enrollment expected by late summer. The company's Strategic Review Committee continues to evaluate alternatives to enhance shareholder value.

Theravance Biopharma (NASDAQ: TBPH) has announced upcoming presentations of analyses from their ampreloxetine Phase 3 program at the International MSA Congress in Boston, May 9-11, 2025. The analyses focus on Studies 169 and 170, supporting ampreloxetine's potential in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients.

The presentations include a plenary oral session and poster sessions featuring:

• A pre-specified subgroup analysis of a phase 3 trial by Norcliffe-Kaufmann L, et al.
• Analysis of symptomatic nOH impact on symptom burden by Iodice V, et al.

These analyses support the ongoing CYPRESS registrational study (NCT05696717) in patients with nOH and MSA, demonstrating the company's commitment to understanding ampreloxetine's selective mechanism of action.

Theravance Biopharma (NASDAQ: TBPH) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 8, 2025, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.

Participants can join via telephone by dialing (800) 715-9871 from the US or (646) 307-1963 internationally, using Conference ID 3369474. The webcast will be accessible through the Investors section of Theravance Biopharma's website and will remain available for replay until June 7, 2025.

Theravance Biopharma (NASDAQ: TBPH) presented new analyses of ampreloxetine, their investigational treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the American Academy of Neurology 2025 Annual Meeting. The analyses from Phase 3 trials demonstrated the drug's selective mechanism and safety profile.

Key findings showed that patients on ampreloxetine experienced a 58% mean increase in venous plasma norepinephrine levels after 4 weeks, with MSA patients showing a 79% increase. The drug demonstrated sustained improvement in orthostatic blood pressure, particularly in MSA patients. Importantly, ampreloxetine showed no worsening of supine hypertension, a common side effect of current FDA-approved treatments that typically carry black-box warnings.

The data came from two Phase 3 trials (Study 0169 and 0170) involving patients with nOH in multiple system atrophy, Parkinson's Disease, and pure autonomic failure. These results support an ongoing registrational study (CYPRESS) in patients with nOH and MSA.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).

The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.

A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.

Theravance Biopharma (NASDAQ: TBPH) has announced new analyses of their Phase 3 ampreloxetine program for Neurogenic Orthostatic Hypotension (nOH) to be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) in San Diego from April 5-9, 2025.

The presentations, scheduled for April 7, 2025, will showcase findings from Studies 169 and 170, which led to the ongoing Phase 3 confirmatory CYPRESS Study 197 focusing on nOH in multiple system atrophy patients. Two key presentations will be delivered:

• NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in nOH Patients
• The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study

Theravance Biopharma (TBPH) reported strong Q4 and FY 2024 results, with YUPELRI achieving record US net sales of $66.7M in Q4 (up 10% YoY) and $238.6M for FY2024 (up 8% YoY). TRELEGY global net sales reached $3.46B in FY2024, up 26% YoY, triggering a $50M milestone payment to TBPH.

Q4 financial highlights include revenue of $18.8M from Viatris collaboration, R&D expenses of $9.5M, and SG&A expenses of $18.5M. The company ended Q4 with $88.4M in cash, excluding the $50M TRELEGY milestone received in February 2025.

For 2025 guidance, TBPH expects R&D expenses of $32-38M and SG&A expenses of $50-60M (excluding share-based compensation). The CYPRESS study for ampreloxetine remains on track to enroll its final patient by mid-2025.